Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mediator of RNA polymerase II transcription subunit 25 (MED25) is a subunit of the multiprotein Mediator complex, which acts as a crucial coactivator bridging DNA-bound transcription factors and the basal RNA polymerase II transcription machinery[6][7]. MED25 possesses several functional domains, including the ACID (activator interaction domain), which binds various transcriptional activators and viral proteins, and a von Willebrand Factor Type A domain for interaction within the Mediator complex[3][7]. It is a key integrative hub for the regulation of transcriptional responses to endogenous and environmental signals, notably in plant hormone and stress signaling in Arabidopsis (jasmonate, abscisic acid, ethylene, and auxin pathways)[1][2][5][8]. In humans, MED25 is involved in gene regulatory networks, is implicated in cancer, and can be targeted by some viral proteins (such as from human respiratory syncytial virus)[4]. There are currently no approved drugs specifically targeting MED25, nor is it established as a clinical biomarker or direct therapeutic target, but it is of high biological interest due to its central regulatory role.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mediator of RNA polymerase II transcription subunit 25 (MED25).